Provectus Biopharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Provectus Biopharmaceuticals has been growing earnings at an average annual rate of 17.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 81% per year.
Key information
17.8%
Earnings growth rate
19.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 81.0% |
| Return on equity | n/a |
| Net Margin | -527.2% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Provectus Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1 | -3 | 2 | -1 |
| 30 Jun 23 | 1 | -3 | 2 | 0 |
| 31 Mar 23 | 1 | -3 | 2 | 0 |
| 31 Dec 22 | 1 | -4 | 2 | 0 |
| 30 Sep 22 | 1 | -4 | 2 | 3 |
| 30 Jun 22 | 1 | -4 | 2 | 0 |
| 31 Mar 22 | 0 | -5 | 2 | 0 |
| 31 Dec 21 | 0 | -6 | 2 | 0 |
| 30 Sep 21 | 0 | -6 | 2 | 1 |
| 30 Jun 21 | 0 | -6 | 2 | 1 |
| 31 Mar 21 | 0 | -7 | 2 | 2 |
| 31 Dec 20 | 0 | -7 | 2 | 3 |
| 30 Sep 20 | 0 | -7 | 2 | 3 |
| 30 Jun 20 | 0 | -7 | 2 | 3 |
| 31 Mar 20 | 0 | -7 | 2 | 4 |
| 31 Dec 19 | 0 | -7 | 2 | 4 |
| 30 Sep 19 | 0 | -8 | 3 | 4 |
| 30 Jun 19 | 0 | -7 | 3 | 4 |
| 31 Mar 19 | 0 | -7 | 3 | 4 |
| 31 Dec 18 | 0 | -8 | 3 | 5 |
| 30 Sep 18 | 0 | -9 | 4 | 5 |
| 30 Jun 18 | 0 | -10 | 3 | 7 |
| 31 Mar 18 | 0 | -12 | 3 | 8 |
| 31 Dec 17 | 0 | -14 | 5 | 8 |
| 30 Sep 17 | 0 | -17 | 8 | 8 |
| 30 Jun 17 | 0 | -23 | 11 | 8 |
| 31 Mar 17 | 0 | -25 | 13 | 8 |
| 31 Dec 16 | 0 | -29 | 16 | 8 |
| 30 Sep 16 | 0 | -32 | 16 | 11 |
| 30 Jun 16 | 0 | -29 | 16 | 11 |
| 31 Mar 16 | 0 | -28 | 15 | 11 |
| 31 Dec 15 | 0 | -25 | 11 | 11 |
| 30 Sep 15 | 0 | -14 | 10 | 9 |
| 30 Jun 15 | 0 | -12 | 10 | 8 |
| 31 Mar 15 | 0 | -8 | 10 | 6 |
| 31 Dec 14 | 0 | -10 | 11 | 6 |
| 30 Sep 14 | 0 | -28 | 10 | 4 |
| 30 Jun 14 | 0 | -28 | 10 | 4 |
| 31 Mar 14 | 0 | -30 | 10 | 4 |
| 31 Dec 13 | 0 | -29 | 9 | 4 |
| 30 Sep 13 | 0 | -14 | 8 | 3 |
| 30 Jun 13 | 0 | -12 | 8 | 3 |
| 31 Mar 13 | 0 | -13 | 9 | 4 |
Quality Earnings: PXY is currently unprofitable.
Growing Profit Margin: PXY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PXY is unprofitable, but has reduced losses over the past 5 years at a rate of 17.8% per year.
Accelerating Growth: Unable to compare PXY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PXY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: PXY's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.